Anergia-anhedonia by Lithium-induced Phosphorus Diabetes

NCT06111664 | Unknown

• 1 other identifier: 8953
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Lithium (Li+) is prescribed to 1‰ of the French population (\~ 60,000 patients). More than half of patients describe subjective symptoms linked to Li+ (SSL) similar to those of chronic fatigue syndrome: muscle weakness, fatigability, cognitive disorders, emotional blunting. SSL are the 2nd cause of stopping Li+ (28%), just behind kidney problems (30%). In animals, the administration of lithium (Li+) increases the urinary excretion of phosphate (Pi) by 6, inducing phosphate diabetes (DPi). However, idiopathic forms of DPi explain up to 10-15% of chronic fatigue syndromes and these disappear when supplementing with Pi (± vitamin D). In humans, the introduction of Li+ leads to a reduction in serum phosphate but we have not found any publication on the possible induction of DPi or on a possible link between DPi and SSL. However, the dosages necessary to detect a DPi are carried out during the annual follow-up assessment of patients on Li+. All you have to do is calculate the standardized maximum reabsorption rate of Pi (TmPi) to make the diagnosis! Finally, if the patients presenting with DPi turn out to be the same as those who complain of SSL, we can imagine that correcting the first by simple supplementation with Pi (± vitamin D) could provide relief.

Conditions

Mood Disorders

Keywords

Diabetes, Phosphate; Anergia-anhedonia; Lithium (Li+); Mood Disorders

Outcome Measures

Primary Outcomes (1)

• Prevalence of hypophosphatemia, DPi and SSL at the population level.

  The prevalence is determined retrospectively on a population balanced on lithium (Li+) for more than 6 months.

  from 6 months after lithium treatment (Li+)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major subject (≥ 18 years old) balanced on Li+ (\> 6 months, regardless of the underlying pathology).

You may qualify if:

• Major subject (≥ 18 years old)
• Man or woman
• Subject balanced on Li+ (\> 6 months, regardless of the underlying pathology).
• Outpatient monitoring by one of the members of CEDRA (Alsace expert center for resistant depression).
• Subject not opposing, after information, the reuse of their data for the purposes of this research

You may not qualify if:

• Subject having expressed opposition to participating in the study
• Subject under judicial protection
• Subject under guardianship or curatorship

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

CENTRE DE NEUROMODULATION NON INVASIVE DE STRASBOURG (CEMNIS) - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Mood Disorders; Hypophosphatemia, Familial

Condition Hierarchy (Ancestors)

Mental Disorders; Renal Tubular Transport, Inborn Errors; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Metal Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases; Hypophosphatemia; Phosphorus Metabolism Disorders

Central Study Contacts

Jack FOUCHER, MD, PhD

CONTACT

33 3 88 11 69 21; jack.foucher@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 26, 2023
• First Posted: November 1, 2023
• Study Start: May 1, 2023
• Primary Completion: April 1, 2024
• Study Completion: April 24, 2024
• Last Updated: November 1, 2023

Record last verified: 2023-10

Locations

FR (1)